66-Country Survey Exposes Barriers to Hemophilia Gene Therapy
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, posted on LinkedIn:
”Haemophilia Gene Therapy: New ISTH survey reveals a critical disconnect between clinical innovation and healthcare readiness.
Global survey assessing knowledge, perceptions, and clinical preparedness for gene therapy among haemophilia professionals. Over eight months (August 2023–January 2024), 327 healthcare professionals from 66 countries responded via an anonymous online questionnaire distributed through four major professional organizations.
Current Therapy Limitations
– burden of dosing schedules and prophylaxis
– of inhibitor development
– with injections and venous access
– and reimbursement pressures
– with treatment adherence
– impact on quality of life and joint disease
– breakthrough bleeding and pain
What Was Found Related to Gene Therapy
– 7.5% feel extremely familiar with gene therapy
– 35.6% uncomfortable answering patient questions about trials
– 60% of patients have never discussed gene therapy with their care team
Major Barriers to Implementation of Gene Therapy
– Durability uncertainty
– Variability in patient response
– Cost and reimbursement challenges
– Restrictive eligibility criteria
– Insufficient healthcare system preparedness
Gene therapy is clinically available. What’s missing is confidence, system readiness, and equitable global access. Closing this gap requires targeted professional education, healthcare pathways, and solutions that ensure all eligible patients – ideally, regardless of geography – can access this transformative treatment.
Published in Therapeutic Advances in Hematology, open access link ”
Title: Gene therapy for hemophilia: results of ISTH global survey on current knowledge, attitudes, and preparedness of the hemophilia care team
Authors: Melissa F. Glasner, Wolfgang Miesbach

Stay informed with Hemostasis Today.
-
Jul 13, 2026, 11:25Luisa Müller: Advancing Anticoagulation Strategies for VITT at ISTH 2026
-
Jul 13, 2026, 10:49Joshua Zeidner: Advancing Menin Inhibitor Therapy in MD Education AML-ALL US Focus 2026
-
Jul 13, 2026, 10:25Flora Peyvandi: A Practical Approach to ALT Elevation After Gene Therapy at ISTH 2026
-
Jul 13, 2026, 10:02Jessica Garcia: Where Science and Community Come Together at ISTH 2026
-
Jul 13, 2026, 09:46Fabrice Cognasse: Is There Such a Thing as the Perfect Platelet Product?
-
Jul 13, 2026, 09:42Cancer-Associated Arterial Thromboembolism: Redefining the Thrombotic Burden in Oncology
-
Jul 13, 2026, 05:59Connecting and Collaborating at ISTH 2026 – NNHF
-
Jul 13, 2026, 05:58Lara Monica: Back at ISTH – Looking Forward to Science and Reconnections!
-
Jul 13, 2026, 05:57Barbara Adams Krolak: Exciting Updates From the ISTH 2026 Regulatory Session